$2.39
-0.04 (-1.65%)
Open$2.40
Previous Close$2.43
Day High$2.47
Day Low$2.32
52W High$2.47
52W Low$0.91
Volume—
Avg Volume5.23M
Market Cap221.46M
P/E Ratio—
EPS$-1.15
SectorBiotechnology
Analyst Ratings
Buy
18 analysts
Price Target
+140.6% upside
Current
$2.39
$2.39
Target
$5.75
$5.75
$4.43
$5.75 avg
$6.69
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 5.18M | 12.63M | 39.14M |
| Net Income | -106,329,779 | -233,293,030 | -10,010,485 |
| Profit Margin | -2,051.1% | -1,948.5% | -25.6% |
| EBITDA | -105,078,840 | -243,356,650 | -16,322,152 |
| Free Cash Flow | — | — | -10,981,777 |
| Rev Growth | -59.0% | -59.0% | +22.5% |
| Debt/Equity | — | — | 0.27 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |